Jakarta, CNBC Indonesia – Corona vaccine made by the German biopharmaceutical company CureVac was said to be ineffective and failed to meet the criteria for success. As a result, CureVac shares plunged 50% in trading on Wednesday (16/6/2021).
In a press release, the vaccine candidate CureVac demonstrated a temporary efficacy of 47% against Covid-19 disease “of any severity”. The company said a final analysis of the results would be completed in the coming weeks.
A late-stage clinical trial of about 40,000 participants in 10 countries found a high prevalence of viral variants. In particular, the Lambda variant of the corona virus which was first detected in South America.
“While we expected stronger interim results, we recognize that demonstrating high efficacy in this unprecedented diversity of variants is a challenge,” CEO Franz-Werner Haas said in a statement. CNBC International.
“As we proceed to the final analysis with a minimum of 80 additional cases, the overall efficacy of the vaccine may change.”
According to the same release, the study also found varying levels of efficacy for different age groups.
CureVac is also working on a separate Covid vaccine candidate in partnership with GlaxoSmithKline. The company hopes to enter clinical trials on that candidate in the third quarter of 2021.
(boss / boss)
– .
